CN103649091B - 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 - Google Patents

取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 Download PDF

Info

Publication number
CN103649091B
CN103649091B CN201280027509.4A CN201280027509A CN103649091B CN 103649091 B CN103649091 B CN 103649091B CN 201280027509 A CN201280027509 A CN 201280027509A CN 103649091 B CN103649091 B CN 103649091B
Authority
CN
China
Prior art keywords
dihydrochloride
formula
period
temperature
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280027509.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103649091A (zh
Inventor
J·G·彼得斯
H-C·米利策尔
H·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103649091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN103649091A publication Critical patent/CN103649091A/zh
Application granted granted Critical
Publication of CN103649091B publication Critical patent/CN103649091B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CN201280027509.4A 2011-04-05 2012-03-29 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 Active CN103649091B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP11161111.7 2011-04-05
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (2)

Publication Number Publication Date
CN103649091A CN103649091A (zh) 2014-03-19
CN103649091B true CN103649091B (zh) 2016-06-22

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280027509.4A Active CN103649091B (zh) 2011-04-05 2012-03-29 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐

Country Status (42)

Country Link
US (2) US10383876B2 (und)
EP (2) EP2508525A1 (und)
JP (2) JP5763834B2 (und)
KR (1) KR101937501B1 (und)
CN (1) CN103649091B (und)
AP (1) AP3709A (und)
AR (1) AR085718A1 (und)
AU (1) AU2012238891B2 (und)
BR (1) BR112013025549A2 (und)
CA (1) CA2832123C (und)
CL (1) CL2013002870A1 (und)
CO (1) CO6781534A2 (und)
CR (1) CR20130511A (und)
CU (1) CU24208B1 (und)
CY (1) CY1116231T1 (und)
DK (1) DK2694508T3 (und)
DO (1) DOP2013000223A (und)
EA (1) EA023646B1 (und)
EC (1) ECSP13013006A (und)
ES (1) ES2529653T3 (und)
GT (1) GT201300234A (und)
HK (1) HK1195907A1 (und)
HR (1) HRP20150138T1 (und)
IL (1) IL228561A (und)
JO (1) JO2958B1 (und)
MA (1) MA35014B1 (und)
ME (1) ME02021B (und)
MX (1) MX336057B (und)
MY (1) MY169452A (und)
PE (1) PE20141038A1 (und)
PL (1) PL2694508T3 (und)
PT (1) PT2694508E (und)
RS (1) RS53811B1 (und)
SG (1) SG193595A1 (und)
SI (1) SI2694508T1 (und)
SM (1) SMT201500037B (und)
TN (1) TN2013000401A1 (und)
TW (2) TWI549954B (und)
UA (1) UA111604C2 (und)
UY (1) UY33985A (und)
WO (1) WO2012136553A1 (und)
ZA (1) ZA201307105B (und)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107864625A (zh) * 2015-03-09 2018-03-30 拜耳制药股份公司 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
SG11201509116VA (en) 2013-06-14 2015-12-30 Bayer Pharma AG Anti-tweakr antibodies and uses thereof
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
JP6815329B2 (ja) 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ｃｅａｃａｍ６抗体およびその使用
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
MX2018009367A (es) 2016-02-01 2018-11-09 Bayer Pharma AG Biomarcadores de copanlisib.
US20190038632A1 (en) 2016-02-01 2019-02-07 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
KR102445255B1 (ko) 2016-03-02 2022-09-22 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
JP6935415B2 (ja) * 2016-03-08 2021-09-15 バイエル ファーマ アクチエンゲゼルシャフト ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
ES2950663T3 (es) * 2017-09-08 2023-10-11 Bayer Pharma AG Formulaciones de copanlisib
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US20210369724A1 (en) * 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
BR112021007377A2 (pt) * 2018-10-17 2021-07-20 Sandoz Ag cocristal, uso do cocristal e composição farmacêutica
EP3903786A4 (en) * 2018-12-27 2022-09-28 Holosmedic NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION TO INCREASE ANTI-CANCER ACTIVITY
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588505A5 (und) 1972-06-08 1977-06-15 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (und) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009091550A2 (en) * 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
AU2016231259A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
WO2008070150A1 (en) * 2006-12-05 2008-06-12 Bayer Schering Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2010034414A1 (en) * 2008-09-24 2010-04-01 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107864625A (zh) * 2015-03-09 2018-03-30 拜耳制药股份公司 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品
CN107864625B (zh) * 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品

Also Published As

Publication number Publication date
AR085718A1 (es) 2013-10-23
ME02021B (me) 2015-05-20
CN103649091A (zh) 2014-03-19
EP2508525A1 (en) 2012-10-10
TWI549954B (zh) 2016-09-21
JP5763834B2 (ja) 2015-08-12
AP2013007219A0 (en) 2013-10-31
TW201637656A (zh) 2016-11-01
HRP20150138T1 (hr) 2015-05-08
CU24208B1 (es) 2016-11-29
DK2694508T3 (en) 2015-02-16
US20160193219A1 (en) 2016-07-07
EP2694508B1 (en) 2014-11-19
UY33985A (es) 2012-10-31
GT201300234A (es) 2015-01-16
PT2694508E (pt) 2015-02-10
CA2832123C (en) 2018-09-11
JP2015164936A (ja) 2015-09-17
AU2012238891B2 (en) 2016-12-01
IL228561A0 (en) 2013-12-31
CL2013002870A1 (es) 2014-06-20
TW201249847A (en) 2012-12-16
MX336057B (es) 2016-01-07
MY169452A (en) 2019-04-11
PE20141038A1 (es) 2014-09-05
CU20130133A7 (es) 2014-01-29
US10383876B2 (en) 2019-08-20
JP2014510119A (ja) 2014-04-24
TN2013000401A1 (en) 2015-03-30
ES2529653T3 (es) 2015-02-24
KR20140021637A (ko) 2014-02-20
ZA201307105B (en) 2014-11-26
EP2694508A1 (en) 2014-02-12
CA2832123A1 (en) 2012-10-11
AP3709A (en) 2016-05-31
SG193595A1 (en) 2013-10-30
BR112013025549A2 (pt) 2016-12-27
EA023646B1 (ru) 2016-06-30
WO2012136553A1 (en) 2012-10-11
JO2958B1 (en) 2016-03-15
US20140072529A1 (en) 2014-03-13
NZ616198A (en) 2015-09-25
DOP2013000223A (es) 2013-11-15
TWI592158B (zh) 2017-07-21
SMT201500037B (it) 2015-05-05
UA111604C2 (uk) 2016-05-25
JP5826961B2 (ja) 2015-12-02
ECSP13013006A (es) 2013-12-31
AU2012238891A1 (en) 2013-10-24
CO6781534A2 (es) 2013-10-31
CY1116231T1 (el) 2017-02-08
CR20130511A (es) 2013-12-04
MX2013011583A (es) 2013-12-16
SI2694508T1 (sl) 2015-03-31
RS53811B1 (en) 2015-06-30
US9636344B2 (en) 2017-05-02
PL2694508T3 (pl) 2015-04-30
KR101937501B1 (ko) 2019-01-10
IL228561A (en) 2015-10-29
EA201391470A1 (ru) 2014-03-31
MA35014B1 (fr) 2014-04-03
HK1195907A1 (zh) 2014-11-28

Similar Documents

Publication Publication Date Title
CN103649091B (zh) 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN102762557B (zh) 三唑并吡啶
CN102858768B (zh) 取代三唑并吡啶
CN103370322B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
CN102413831B (zh) 取代的咪唑并喹喔啉
CN103764656A (zh) 杂环基氨基咪唑并哒嗪
CN103687858A (zh) 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
CN104797585A (zh) 氨基咪唑并哒嗪
CN103429591A (zh) 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
CN102137846B (zh) N-(2-氨基苯基)-4-[n-(吡啶-3-基)甲氧基羰基氨基甲基]苯甲酰胺(ms-275)多晶型物b
CN105008363A (zh) 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
CN103228274A (zh) 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合
CN103415518A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CN104284896A (zh) 取代的咪唑并哒嗪
CN106414435A (zh) 氨基‑取代的异噻唑
CN107108636A (zh) 6‑羟基苯并呋喃基‑和6‑烷氧基苯并呋喃基‑取代的咪唑并哒嗪
NZ616198B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US20160045496A1 (en) Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195907

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1195907

Country of ref document: HK

CP02 Change in the address of a patent holder

Address after: On the Rhine River, Germany

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Germany

Patentee before: BAYER INTELLECTUAL PROPERTY GmbH

CP02 Change in the address of a patent holder